Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Geron Corporation    GERN

GERON CORPORATION (GERN)
Mes dernières consult.
Most popular
Rapport
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/13/2017 10/16/2017 10/17/2017 10/18/2017 10/19/2017 Date
2.12(c) 2.08(c) 2.09(c) 2.08(c) 2.075 Last
1 146 987 1 230 970 754 631 423 240 242 569 Volume
-0.93% -1.89% +0.48% -0.48% -0.24% Change
More quotes
Financials ($)
Sales 2017 1,25 M
EBIT 2017 -29,9 M
Net income 2017 -27,9 M
Debt 2017 -
Yield 2017 -
Sales 2018 31,0 M
EBIT 2018 -4,03 M
Net income 2018 -28,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 265x
Capi. / Sales2018 10,7x
Capitalization 331 M
More Financials
Company
Geron Corp. discovers and develops therapeutic products for cancer.It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park,... 
More about the company
Surperformance© ratings of Geron Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on GERON CORPORATION
09/22 GERON CORP : Entry into a Material Definitive Agreement, Financial Statements an..
09/21 GERON : to Present at the Cantor Fitzgerald Healthcare Conference
09/19 Geron to Present at the Cantor Fitzgerald Healthcare Conference
09/01 GERON CORPORATION : Today's Research Reports on Trending Tickers: Geron Corporat..
08/10 GERON CORPORATION (NASDAQ : GERN) reported earnings of ($0.04) per share beating..
08/09 GERON : reports 2Q loss
08/09 GERON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
08/09 GERON CORP : Results of Operations and Financial Condition, Financial Statements..
08/09 GERON CORPORATION : Reports Second Quarter 2017 Financial Results
08/01 GERON CORP : Other Events, Financial Statements and Exhibits (form 8-K)
More news
Sector news : Bio Therapeutic Drugs
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Bio Therapeutic Drugs
Latest Tweets
12:11pGrifols : Breakfast Technical Briefing on Biotech Stocks -- Coherus Bioscienc.. 
10:59aLegal & General Group Plc Has $117,000 Holdings in Geron Corporation $GER.. 
05:40a$GERN - Somewhat Positive Press Coverage Somewhat Unlikely to Affect Geron Co.. 
05:21aSomewhat Positive Press Coverage Somewhat Unlikely to Affect Geron Corporatio.. 
10/18Head to Head Analysis: Geron Corporation $GERN & Its Rivals  
More tweets
Qtime:43
News from SeekingAlpha
09/27 Geron (GERN) Presents At Cantor Fitzgerald Global Healthcare Conference - Sli..
09/26 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 26, 2017
09/20 YOUR DAILY PHARMA SCOOP : Geron's Growth Potential, Ipsen's Xarmelo Approval, GS..
08/10 GERON'S IMETELSTAT : Obstacles To Success
08/09 Geron beats by $0.01, misses on revenue
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | GERN | US3741631036 | 4-Traders
Technical analysis trends GERON CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
John A. Scarlett President, Chief Executive Officer & Director
Ho Young Huh Chairman
Olivia K. Bloom Chief Financial Officer, Treasurer & Executive VP
Karin Eastham Independent Director
Robert Jay Spiegel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GERON CORPORATION0.48%331
GILEAD SCIENCES11.73%104 487
REGENERON PHARMACEUTICALS19.69%47 079
VERTEX PHARMACEUTICALS110.07%39 018
ACTELION23.81%29 869
GENMAB14.75%12 912